318 related articles for article (PubMed ID: 36465385)
1. Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.
Shen J; Liu J
Front Oncol; 2022; 12():1034668. PubMed ID: 36465385
[TBL] [Abstract][Full Text] [Related]
2. Bruton's tyrosine kinase inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A meta-analysis and systematic review.
Guo HP; Dang XL; Kang L; Liu C; Liu XW
World Neurosurg; 2024 Apr; ():. PubMed ID: 38641241
[TBL] [Abstract][Full Text] [Related]
3. Targets and treatments in primary CNS lymphoma.
von Roemeling C; Ferreri AJM; Soussain C; Tun HW; Grommes C
Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38659230
[TBL] [Abstract][Full Text] [Related]
4. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
[TBL] [Abstract][Full Text] [Related]
5. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma.
Steffanoni S; Batchelor TT
Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302
[TBL] [Abstract][Full Text] [Related]
6. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
Schaff L; Nayak L; Grommes C
Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38597202
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors.
Aghel N; Baro Vila RC; Lui M; Hillis C; Leong DP
Curr Cardiol Rep; 2023 Sep; 25(9):941-958. PubMed ID: 37498449
[TBL] [Abstract][Full Text] [Related]
8. [Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].
Song J; Liu H; Shen HL; Yue LZ; Yang XJ; Song WJ; Sun CY; Yu SZ; Ding K; Wang YH; Li LJ; Yu H; Shao YY; Wang CM; Yue SY; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):917-922. PubMed ID: 35045653
[No Abstract] [Full Text] [Related]
9. Clinical characteristics and prognosis of patients with newly diagnosed primary central nervous system lymphoma: a multicentre retrospective analysis.
Bai SJ; He JX; Zheng YJ; Geng Y; Gao YN; Zhang CX; Wang YR; Qin LY; Wang WJ; Yang LH
Ann Hematol; 2024 May; ():. PubMed ID: 38761184
[TBL] [Abstract][Full Text] [Related]
10. Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Hatashima A; Karami M; Shadman M
Expert Opin Pharmacother; 2022 Sep; 23(13):1545-1557. PubMed ID: 35973973
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma.
Wirsching HG; Weller M; Balabanov S; Roth P
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203062
[TBL] [Abstract][Full Text] [Related]
12. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.
Paillassa J; Safa F; Troussard X
Ther Adv Hematol; 2022; 13():20406207221090886. PubMed ID: 35450208
[TBL] [Abstract][Full Text] [Related]
13. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
Sasaki N; Nagane M
No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
[TBL] [Abstract][Full Text] [Related]
14. Recent Progress on Primary Central Nervous System Lymphoma-From Bench to Bedside.
Shao L; Xu C; Wu H; Jamal M; Pan S; Li S; Chen F; Yu D; Liu K; Wei Y
Front Oncol; 2021; 11():689843. PubMed ID: 34485125
[TBL] [Abstract][Full Text] [Related]
15. The Use of Bruton's Tyrosine Kinase Inhibitors to Treat Allergic Disorders.
Dispenza MC
Curr Treat Options Allergy; 2021; 8(3):261-273. PubMed ID: 33880321
[TBL] [Abstract][Full Text] [Related]
16. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
Nagane M
Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
[TBL] [Abstract][Full Text] [Related]
18. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
[TBL] [Abstract][Full Text] [Related]
19. Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.
Campbell R; Chong G; Hawkes EA
J Clin Med; 2018 Mar; 7(4):. PubMed ID: 29561760
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Thompson MC; Mato AR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
